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Type 2 diabetes is characterized by insulin resistance, and the hyperinsulinemia commonly observed in
patients is thought to be a compensatory response. Yet it has been difficult to disentangle cause and effect.
Mehran et al. (2012) provide genetic evidence that a reduction of insulin secretion prevents high-fat feeding-
induced obesity.Type 2 diabetes mellitus (DM2) is often
associated with obesity, and both condi-
tions are characterized by insulin resis-
tance and increased insulin levels.
Hyperinsulinemia is considered to be a
compensatory response to insulin resis-
tance, which allows us to maintain glu-
cose and lipid homeostasis during states
of increased insulin resistance such as
illness or stress. In the clinic, it is almost
always possible to control glycemia in
individuals with DM2 by giving more
insulin. However, there is also some data
suggesting that prolonged hyperinsuline-
mia per se can induce insulin resistance.
Thus the question of whether hyperinsuli-
nemia is the ‘‘cart or the horse’’ is highly
relevant—yet hard to dissect (reviewed
in Shanik et al., 2008). Mehran et al.
(2012) now reveal that lowering hyperin-
sulinemia has the beneficial effect of pre-
venting high-fat feeding-induced obesity.
To study the role of hyperinsulinemia in
obesity and insulin resistance, Mehran
et al. (2012) used a genetic approach to
limit insulin secretion from pancreatic
b cells in mice. From a technical stand-
point this was a complicated undertaking
due to the fact that, whereas humans
have only one insulin gene, mice have
two, Ins1 and Ins2. Further, insulin is
expressed not only in pancreatic b cells
but also in the brain, especially during
development, where it conceivably could
act locally and regulate neuronal develop-
ment and energy homeostasis (Plum
et al., 2006). Mehran et al. (2012) first
demonstrated that only Ins2 is expressed
in the CNS, whereas Ins1 is restricted to
pancreatic b cells. They then generated
a mouse model lacking both alleles
of the Ins2 gene and one allele of the
Ins1 gene. The resulting hypomorphIns1+/:Ins2/ mice, which express
insulin in b cells only, could then be
compared to control mice. Although this
approach reduced the expression of
insulin mRNA in the pancreas by 50% as
expected, insulin secretion was still com-
parable between Ins1+/:Ins2/ mice
and controls, possibly due to posttransla-
tional compensation.
To determine how Ins1 haploinsuffi-
ciency affects susceptibility to insulin re-
sistance and obesity, the authors placed
the mice on a high-fat diet. For the first
few weeks, insulin secretion increased
about 3-fold in the Ins1+/:Ins2/
mice, compared to about 6-fold in the
controls. Surprisingly, however, whereas
the controls gained significantly more
weight on high-fat diet than animals on
chow diet, the Ins1+/:Ins2/ mice did
not. At 1 year of age, after 10 months of
high-fat feeding, the Ins1+/:Ins2/
mice were still as lean as animals fed the
control diet and protected from high-fat
diet-induced hepatic steatosis and dysli-
pidemia, and they did not exhibit hyperin-
sulinemia anymore.
What do these findings tell us about the
relative roles of insulin and adiposity in
metabolic diseases? Most genetic mouse
models protected from high-fat diet-
induced obesity are also metabolically
protected and, for example, do not
develop hepatosteatosis and dyslipide-
mia. While the level of adiposity may
appear to be the primary variable and,
potentially, be seen as the driver of the
metabolic phenotype, one should re-
member that the differences in adiposity
are not only a consequence of increased
adipocyte growth but are primarily due to
alterations in energy expenditure. Indeed,
while Ins1+/:Ins2/ mice have similarCell Metabolism 16,food intake as controls, they exhibit an
increase in energy expenditure, which
likely accounts for the differences in
adiposity. Thus, the lack of dysmetabolic
features could be a direct consequence
of increased energy expenditure and
decreased adiposity. Extensive gene-
expression profiling of adipose tissue
from Ins1+/:Ins2/ mice supports this
notion. Mehran et al. (2012) observed
increased expression of genes under the
control of sympathetic outflow, such as
uncoupling protein 1 (UCP1). Since
UCP1 uncouples mitochondrial respira-
tion from ATP production and facilitates
the burning of energy, increased UCP1
expression may potentially account for
someof thedifferences in energyexpendi-
ture. So how do Ins1+/:Ins2/ mice
increase energy expenditure and thereby
stay lean when fed a high-fat diet while
controlmice are unable todo so? It is likely
that hyperinsulinemia creates a feed-
forward loop via b cell insulin resistance
that may increase basal insulin release in
the context of overnutrition. But why is
the initial hyperinsulinemia seen in the
Ins1+/:Ins2/ mice not sufficient to
do the same? One reason for the in-
creased energy expenditure may be that
lower hyperinsulinemia could allow for
a higher sympathetic tone as insulin can
reduce sympathetic outflow to adipose
tissue. Although this is an important regu-
latory mechanism involved in the dynamic
regulation of fasting to feeding transition
(Scherer et al., 2011), chronic hyperin-
sulinemia may actually cause sympa-
thetic insufficiency, which often is seen
in obesity. The adipose tissue gene-
expression profiles lend support to this
hypothesis. Another possibility is that the
Ins1+/:Ins2/ mice maintain a moreDecember 5, 2012 ª2012 Elsevier Inc. 691
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Previewspulsatile insulin secretion profile and that
this mechanism prevents the develop-
ment of insulin resistance (Matveyenko
et al., 2012) and possibly obesity, which
may be the subject of future studies.
The authors were unable to show
increased insulin resistance in high-fat-
fed control mice, as this would be
expected in this mouse strain, which
could be due to a lack of sensitivity of
the insulin tolerance test and would need
to be tested with euglycemic clamp
studies; it is therefore not definitive that
Ins1 haploinsufficiency prevents high-fat
diet-induced insulin resistance. It would
be interesting to probe this question
in the Ins1+/:Ins2/ mice or to re-
plicate these findings in an inducible
Ins1+/:Ins2/ model where haploin-
sufficiency for Ins1 can be induced in
adulthood after normal development.
What are the clinical implications of
these findings? Many interventions used
to treat DM2, such as exercise, weight
loss, and drugs, including metformin and
tiazolidinediones, decrease circulating
insulin levels. What remains unclear is
how each drug affects insulin secretion692 Cell Metabolism 16, December 5, 2012 ªindependent of its effects on insulin
action. It may be possible to specifically
inhibit either insulin secretion or insulin
signaling. For instance, K(ATP) channel
openers, which reduce insulin secretion
from b cells, such as diazoxide, would
unlikely be safe in DM2 but may be bene-
ficial in the prediabetic state before the
onset of relative insulin deficiency. Alter-
natively, one could interfere with insulin
binding to the insulin receptor through
insulin antagonists (Scha¨ffer et al., 2008).
Reducing insulin signaling could mimic
decreased pancreatic insulin secretion.
However, such approaches would require
significant further research to ensure their
safety, as the risks of negatively affecting
glycemic control are significant. A second
important implication is that these studies
point to the potential risk of over-treating
type 2 diabetics with too much insulin
and worsening insulin resistance. This
concern is particularly relevant given that
some insulin analogs, about to be intro-
duced into clinical practice, have increas-
ingly long half-lives that exceed 24 hr.
As any good research, Mehran et al.
(2012) raises many questions that await2012 Elsevier Inc.answers. Thus, while the observation
that Ins1 haploinsuficiency prevents
high-fat feeding induced obesity is pro-
vocative, it would be important to deter-
mine if it prevents insulin resistance,
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